VivoSeq
Other

Therapeutics

0

Pipeline Programs

5

Active Trials

2

Companies Involved

Therapeutics is an early-stage landscape with 0 programs across 2 companies. The most active players are Prometic Biotherapeutics, Inc., AstraZeneca.

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

83/100

Attrition Rate

8/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

12

clinical trials

Completed5 · 42%
Recruiting3 · 25%
Active, not recruiting2 · 17%
Terminated1 · 8%
Unknown status1 · 8%

Trial Activity

12 trials

Treatment of UC With Novel Therapeutics
Recruiting··Phase 2·NCT06420375·20 enrolled
AZD9291 in Combination With Ascending Doses of Novel Therapeutics
Active, not recruiting·AstraZeneca logoAstraZeneca·Phase 1·NCT02143466·344 enrolled
Anhedonia, Development, and Emotions: Phenotyping and Therapeutics
Completed··Phase 4·NCT05487885·123 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)